New combo attack on tough breast cancer
NCT ID NCT04448886
Summary
This study is testing whether adding an immunotherapy drug (pembrolizumab) to a targeted cancer drug (sacituzumab govitecan) works better than the targeted drug alone for people with a specific type of advanced breast cancer that has stopped responding to hormone therapy. About 110 participants with HR-positive, HER2-negative metastatic breast cancer will be randomly assigned to receive one of the two treatment plans. The main goal is to see which approach keeps the cancer from growing for a longer time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
DF/BWCC in Clinical Affiliation with South Shore Hospital
South Weymouth, Massachusetts, 02190, United States
-
DFCI @ Foxborough
Foxborough, Massachusetts, 02035, United States
-
DFCI @ Milford Regional Hospital
Milford, Massachusetts, 01757, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Emory University/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
University of Chicago Medical Center
Chicago, Illinois, 60637, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
-
University of Pennsylvania-Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.